The notice came shortly after an advisory panel meeting at which members debated the pros and cons of asking manufacturers to ...

In combination with Pfizer’s CDK4/6 inhibitor Ibrance (palbociclib) and anti-oestrogen drug Faslodex (fulvestrant), Itovebi ...

In summary, although deal volume is down, there are fewer but larger deal sizes. Life sciences companies that can demonstrate ...

A full house was in Croke Park on Wednesday, May 14 for the inaugural All-Island Cancer Summit, which marked its presence ...